SparX Biotech(Jiangsu) Co., Ltd.
2 clinical trials · Sponsor
◉ Watch SparX Biotech(Jiangsu) Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (NCT06259552) | SparX Biotech(Jiangsu) Co., Ltd. | 2024-03-20 |
| Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors (NCT05231733) | SparX Biotech(Jiangsu) Co., Ltd. | 2022-05-01 |
Track SparX Biotech(Jiangsu) Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.